Alx oncology to host r&d webcast event highlighting its novel egfr targeting antibody-drug conjugate, alx2004, on may 20, 2025

South san francisco, calif., may 13, 2025 (globe newswire) -- alx oncology holdings inc., ("alx oncology" or the "company") (nasdaq: alxo), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that it will host a webcast event on may 20, 2025, to provide an update on alx2004, the company's potentially best- and first-in-class investigational antibody-drug conjugate (adc). the webcast will highlight the novel mechanism of action, preclinical data and clinical development strategy for alx2004 following clearance of the investigational new drug application from the u.s. food and drug administration earlier this year.
ALXO Ratings Summary
ALXO Quant Ranking